Table 2.
Baseline characteristics of patients with V600E vs V600K metastatic melanoma (immunotherapy cohort).
| Characteristics | V600E (n=84) | V600K (n=19) | P-value |
|---|---|---|---|
| Age (years) | |||
| Median | 51 | 61.5 | 0.0358 |
| Gender (N, %) | 0.001 | ||
| Female | 41 (49%) | 3 (16%) | |
| Male | 43 (51%) | 16 (84%) | |
| AJCC stage2 (N, %) | 0.7571 | ||
| IIIC-M1b | 18 (21%) | 3 (16%) | |
| M1c | 66 (79%) | 16 (84%) | |
| LDH (N, %) | 0.1195 | ||
| Normal | 49 (58%) | 15 (79%) | |
| Elevated | 35 (42%) | 4 (21%) | |
| ECOG (N, %) | 0.2037 | ||
| 0 | 42 (50%) | 13 (68%) | |
| ≥1 | 42 (50%) | 6 (32%) | |
| Prior MAPKi (N, %) | 0.8042 | ||
| No | 47 (56%) | 11 (58%) | |
| Yes | 37 (44%) | 8 (42%) | |
| PD1 therapy (N, %) | 0.0229 | ||
| Nivolumab | 22 | 2 | |
| Pembrolizumab | 62 | 17 |
2
AJCC v7 anatomic staging, excluding LDH and brain metastases